Broadview Ventures Appoints Cardiovascular Leader and Biotech Executive Michael Mendelsohn, MD to its Strategic Advisory Board

Broadview Ventures Appoints Cardiovascular Leader and Biotech Executive Michael Mendelsohn, MD to its Strategic Advisory Board

Nov 30, 2022

BOSTON – November 30, 2022 – Broadview Ventures, a mission-driven, cardiovascular health-focused investment organization, today announced the appointment of Michael E. Mendelsohn, MD to its Strategic Advisory Board.  Dr. Mendelsohn is an internationally recognized cardiovascular physician-scientist, industry research leader and biopharma executive with four decades of broad healthcare and medical experience.

Dr. Mendelsohn is the Founder and Chairman of the Board of Cardurion Pharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases.   He currently also serves as a Board Director for Foghorn Therapeutics (NASDAQ: FHTX) and Cyclerion Therapeutics (NASDAQ: CYCN), and as Senior Advisor and consultant to the President of Research & Development  at Takeda Pharmaceuticals. Dr. Mendelsohn is a Professor of Medicine at Tufts University School of Medicine.

“We are thrilled to add an experienced cardiovascular leader and innovator of Michael’s caliber to our Strategic Advisory Board,” said Christopher Colecchi, Managing Director of Broadview Ventures.  “We look forward to leveraging his vast expertise and insights as we continue to advance our mission-driven approach to investing and supporting impactful companies focused on bringing innovative technologies to patients in need.”

Prior to founding Cardurion Pharmaceuticals, Dr. Mendelsohn served as SVP and Global Head of Cardiovascular Diseases at Merck & Co.  In this role, he had responsibility for all cardiovascular research, from early drug discovery through late clinical development and directed preclinical and clinical programs in heart failure, atherosclerosis, resistant hypertension, and thrombosis.  Previously, Dr. Mendelsohn worked for 25 years as an academic cardiovascular physician-scientist in Boston.  He spent 17 years at Tufts Medical Center, where he served as the first-ever Chief Scientific Officer and the Executive Director of the center’s Molecular Cardiology Research Institute.

“I’m excited to work with a mission-driven organization that shares my passion and dedication to improving cardiovascular healthcare outcomes across patient populations,” said Dr. Mendelsohn.  “I look forward to contributing to Broadview Ventures’ important efforts to advance the field through targeted investments in great science.”

Dr. Mendelsohn received his undergraduate degree in Chemistry and English from Amherst College and his M.D. from Harvard Medical School.  He completed his residency in internal medicine and fellowship in cardiovascular medicine at the Brigham and Women’s Hospital in Boston.  As an academic physician-scientist, Dr. Mendelsohn’s research has focused on signal transduction pathways regulating vascular and myocardial function. He has been the principal investigator on numerous National Institutes of Health awards and is an elected member of the American Society of Clinical Investigation (ASCI), the Association of University Cardiologists (AUC) and the Association of American Physicians (AAP).